This study aims to investigate the therapeutic potential of pomegranate in the treatment of MASLD
People who stayed on their GLP-1 medication continuously had an 82 percent lower risk of cardiovascular events like heart attack, stroke, or death during the three-year study period than those who took a sulfonylurea
Martin Makary, is a doctor, just like me, who has sworn to prioritize the well-being of patients and first, do no harm. I urge him to pause enforcement action to look at all the solid evidence and clinical and public health implications of the decisions that preceded him, as we, as physicians, are trained to do
Third-party credential presentation is one of the stronger proxy indicators available for consumers evaluating telehealth pharmacy legitimacy
Pemvidutide Structure [6] On November 13, 2023, Altimmune presented the results of their Phase II clinical trial (NCT05292911) for Pemvidutide in the treatment of NAFLD at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting